# A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

> **NCT00987935** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 134 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT00987935
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2014-07
- **Final completion:** 2016-01
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00987935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00987935, "A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00987935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*